 NEW YORK, Feb. 17, 2021 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics Journal of the American Academy of Pediatrics has published a paper on the first two children treated with Mesoblasts mesenchymal stromal cell MSC product candidate remestemcel-L for life-threatening multisystem inflammatory syndrome MIS-C associated with COVID-19. 